KYORIN Pharmaceutical Co.,Ltd. (JP:4569)
:4569
Want to see JP:4569 full AI Analyst Report?
4569 Stock Chart & Stats
¥1537.00
-¥23.00(-1.53%)
At close: 4:00 PM EST
¥1537.00
-¥23.00(-1.53%)
Day’s Range― - ―
52-Week Range¥1,359.00 - ¥1,725.00
Previous CloseN/A
Volume61.80K
Average Volume (3M)127.03K
Market Cap
¥81.17B
Enterprise Value¥104.40B
Total Cash (Recent Filing)¥16.62B
Total Debt (Recent Filing)¥26.48B
Price to Earnings (P/E)27.4
Beta0.55
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.36%
Share Statistics
EPS (TTM)179.30
Shares Outstanding59,945,640
10 Day Avg. Volume147,840
30 Day Avg. Volume127,030
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)0.63
Price to Sales (P/S)0.66
P/FCF Ratio-39.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)77.6
Revenue Forecast (FY)¥125.58B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent mid-single-digit top-line growth demonstrates durable commercial momentum in KYORIN's core therapeutic areas. Sustained revenue expansion supports reinvestment in R&D and commercialization, helps absorb regulatory price shifts, and underpins longer-term earnings stability.
Strong Profitability MarginsHigh gross margin and improving net margin reflect structural cost control and pricing power in branded prescription products. Healthy margins enhance cash generation potential when operating cash conversion improves and provide room to fund pipeline and marketing without immediately diluting returns.
Conservative Capital StructureA strong equity ratio and low leverage give KYORIN financial flexibility to fund development, M&A, or absorb shocks without heavy refinancing. Conservative balance sheet reduces solvency risk and supports multi-quarter investment planning even amid cyclical revenue or pricing pressures.
Bears Say
Negative Free Cash FlowPersistently negative free cash flow indicates the business is not yet converting profits into sustainable cash; this constrains organic funding for R&D, commercial expansion, or dividends. Continued deficits may require external financing or asset monetization, raising long-term cost of capital.
Declining Cash ReservesShrinking cash balances weaken short-term liquidity cushions and limit tactical investments or responses to competitive threats. Over a multi-quarter horizon this elevates refinancing and timing risk for capital projects and could force reprioritization of pipeline spend.
Exposure To Japan NHI PricingRevenue and margin are structurally exposed to Japan's NHI pricing and reimbursement framework. Periodic price adjustments or policy shifts can materially compress pricing power and volumes for core products, creating ongoing regulatory revenue risk that must be managed long-term.
KYORIN Pharmaceutical Co.,Ltd. News
4569 FAQ
What was KYORIN Pharmaceutical Co.,Ltd.’s price range in the past 12 months?
KYORIN Pharmaceutical Co.,Ltd. lowest stock price was ¥1359.00 and its highest was ¥1725.00 in the past 12 months.
What is KYORIN Pharmaceutical Co.,Ltd.’s market cap?
KYORIN Pharmaceutical Co.,Ltd.’s market cap is ¥81.17B.
When is KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date?
KYORIN Pharmaceutical Co.,Ltd.’s upcoming earnings report date is Aug 04, 2026 which is in 81 days.
How were KYORIN Pharmaceutical Co.,Ltd.’s earnings last quarter?
KYORIN Pharmaceutical Co.,Ltd. released its earnings results on May 12, 2026. The company reported -¥11.68 earnings per share for the quarter, missing the consensus estimate of N/A by -¥11.68.
Is KYORIN Pharmaceutical Co.,Ltd. overvalued?
According to Wall Street analysts KYORIN Pharmaceutical Co.,Ltd.’s price is currently Overvalued.
Does KYORIN Pharmaceutical Co.,Ltd. pay dividends?
KYORIN Pharmaceutical Co.,Ltd. pays a Semiannually dividend of ¥37 which represents an annual dividend yield of 3.36%. See more information on KYORIN Pharmaceutical Co.,Ltd. dividends here
What is KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate?
KYORIN Pharmaceutical Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does KYORIN Pharmaceutical Co.,Ltd. have?
KYORIN Pharmaceutical Co.,Ltd. has 59,945,640 shares outstanding.
What happened to KYORIN Pharmaceutical Co.,Ltd.’s price movement after its last earnings report?
KYORIN Pharmaceutical Co.,Ltd. reported an EPS of -¥11.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.259%.
Which hedge fund is a major shareholder of KYORIN Pharmaceutical Co.,Ltd.?
Currently, no hedge funds are holding shares in JP:4569
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
KYORIN Pharmaceutical Co.,Ltd.
KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Towa Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---